End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.

Erythropoisis stimulating agent (ESA) use was addressed in Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) meetings between 2004 and 2008. FDA safety-focused regulatory actions occurred in 2007 and 2008. In 2007, black box warnings advised of early death and venous thrombo...

Full description

Bibliographic Details
Main Authors: Shamia Hoque, Brian J Chen, Martin W Schoen, Kenneth R Carson, Jesse Keller, Bartlett J Witherspoon, Kevin B Knopf, Y Tony Yang, Benjamin Schooley, Chadi Nabhan, Oliver Sartor, Paul R Yarnold, Paul Ray, Laura Bobolts, William J Hrushesky, Michael Dickson, Charles L Bennett
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0234541